149 related articles for article (PubMed ID: 11468201)
1. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Gilchrist IC; O'Shea JC; Kosoglou T; Jennings LK; Lorenz TJ; Kitt MM; Kleiman NS; Talley D; Aguirre F; Davidson C; Runyon J; Tcheng JE
Circulation; 2001 Jul; 104(4):406-11. PubMed ID: 11468201
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
Tcheng JE; Talley JD; O'Shea JC; Gilchrist IC; Kleiman NS; Grines CL; Davidson CJ; Lincoff AM; Califf RM; Jennings LK; Kitt MM; Lorenz TJ
Am J Cardiol; 2001 Nov; 88(10):1097-102. PubMed ID: 11703951
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Tardiff BE; Jennings LK; Harrington RA; Gretler D; Potthoff RF; Vorchheimer DA; Eisenberg PR; Lincoff AM; Labinaz M; Joseph DM; McDougal MF; Kleiman NS;
Circulation; 2001 Jul; 104(4):399-405. PubMed ID: 11468200
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
Gilchrist IC
Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
[TBL] [Abstract][Full Text] [Related]
7. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
8. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Tcheng JE; Harrington RA; Kottke-Marchant K; Kleiman NS; Ellis SG; Kereiakes DJ; Mick MJ; Navetta FI; Smith JE; Worley SJ
Circulation; 1995 Apr; 91(8):2151-7. PubMed ID: 7697843
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
12. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
[TBL] [Abstract][Full Text] [Related]
16. The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.
Vavalle JP; Stevens SR; Hassinger N; Cohen MG; Arnold A; Kandzari DE; Aguirre FV; Gretler DD; Alexander JH
Am Heart J; 2011 Dec; 162(6):996-1002. PubMed ID: 22137072
[TBL] [Abstract][Full Text] [Related]
17. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
Lancet; 1997 May; 349(9063):1422-8. PubMed ID: 9164315
[TBL] [Abstract][Full Text] [Related]
18. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
O'Shea JC; Tcheng JE
Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697
[TBL] [Abstract][Full Text] [Related]
19. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Plosker GL; Ibbotson T
Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
[TBL] [Abstract][Full Text] [Related]
20. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]